Relationship between serum PD-L1 levels and prognosis of gastric cancer patients

Abstract

Abstract:

ObjectiveTo analyze the serum PD-L1 levels of gastric cancer patients and its relationship with tumor stage and prognosis.MethodsSerum of sixty patients with pathological diagnosis of gastric cancer in our hospital from August 2018 to December 2019 were collected, and the serum of 15 healthy adults as a control. The serum PD-L1 levels was measured by enzyme linked immunosorbent assay(ELISA). The serum PD-L1 levels between gastric cancer patients and healthy adults were compared.The relationship between the serum PD-L1 levels and prognosis of gastric cancer patients with different stages was analyzed. Finally, the PD-L1 expression in tumor tissues was detected by immunohistochemical staining, and its correlation with serum PD-L1 levels was analyzed.ResultsThe serum PD-L1 levels of gastric cancer group was significantly higher than that of the control group. The serum PD-L1 levels in patients with stage Ⅲ and Ⅳ gastric cancer was significantly higher than that in stage Ⅰ and Ⅱ. The serum PD-L1 levels in gastric cancer patients with peritoneal metastasis was significantly elevated, indicating poor prognosis. Kaplan-Meier survival analysis showed that the survival time of gastric cancer patients with higher level of serum PD-L1 was shorter than those with lower ones. We further evaluated the PD-L1 expression in tumor tissues. There was no significant correlation between the serum PD-L1 levels and that in tumor tissues.ConclusionsThe serum PD-L1 levels of gastric cancer patients was higher than that of healthy adults, and which gradually increased with the progression of the disease. Gastric cancer patients with peritoneal metastasis had a much higher serum PD-L1 levels, and there was no significant correlation between serum PD-L1 levels and PD-L1 expression in tumor tissues.

Key words:Gastric cancer,Programmed death-ligand 1（PD-L1）,Serum

CLC Number:

R735.2

CHEN Changqiang, YAN Xiaowei, HU Jiele, BAO Xiting, XIANG Ming, JIANG Songyao. Relationship between serum PD-L1 levels and prognosis of gastric cancer patients[J]. Journal of Surgery Concepts & Practice, 2024, 29(03): 230-235.

Figures/Tables6

Fig 1

Fig 2

Fig 3

Item	Sum of squares	Degrees of freedom	Mean square	Fvalue	signifi- cance
Inter group	12 594.041	4	3 148.510	33.576	0.000
Intra group	6 564.002	70	93.771
Total	19 158.044	74

Tab 1

Fig 4

Fig 5

References19

[1]	BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[2]	CUNNINGHAM S C, KAMANGAR F, KIM M P, et al. Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution[J].J Gastrointest Surg,2005,9(5):718-725. doi:10.1016/j.gassur.2004.12.002pmid:15862270
[3]	BANG Y J, VAN CUTSEM E, FEYEREISLOVA A, et al. Trastuzumab in combination with chemotherapyversuschemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial[J].Lancet,2010,376(9742):687-697.
[4]	DONG H, ZHU G, TAMADA K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion[J].Nat Med,1999,5(12):1365-1369. doi:10.1038/70932pmid:10581077
[5]	FREEMAN G J, LONG A J, IWAI Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation[J].J Exp Med,2000,192(7):1027-1034. doi:10.1084/jem.192.7.1027pmid:11015443
[6]	ZOU W, CHEN L. Inhibitory B7-family molecules in the tumour microenvironment[J].Nat Rev Immunol,2008,8(6):467-477. doi:10.1038/nri2326pmid:18500231
[7]	CURIEL T J, WEI S, DONG H, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity[J].Nat Med,2003,9(5):562-567. doi:10.1038/nm863pmid:12704383
[8]	BRAHMER J, RECKAMP K L, BAAS P, et al. Ni-volumabversusdocetaxel in advanced squamous-cell non-small-cell lung cancer[J].N Engl J Med,2015,373(2):123-135.
[9]	LARKIN J, CHIARION-SILENI V, GONZALEZ R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma[J].N Engl J Med,2015,373(1):23-34.
[10]	BÖGER C, BEHRENS H M, MATHIAK M, et al. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients[J].Oncotarget,2016,7(17):24269-24283. doi:10.18632/oncotarget.8169pmid:27009855
[11]	CHEN Y, WANG Q, SHI B, et al. Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines[J].Cytokine,2011,56(2):231-238. doi:10.1016/j.cyto.2011.06.004pmid:21733718
[12]	GU L, CHEN M, GUO D, et al. PD-L1 and gastric cancer prognosis: systematic review and meta-analysis[J].PLoS one,2017,12(8):e0182692.
[13]	QING Y, LI Q, REN T, et al. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer[J].Drug Des Devel Ther,2015,9:901-909.
[14]	王玉丰, 姚南, 王军, 等. PD-1和PD-L1与胃癌患者预后相关性的Meta分析[J].肿瘤防治研究,2020,47(5):346-352.
	WANG Y F, YAO N, WANG J, et al. Meta analysis of the correlation between PD-1 and PD-L1 with the prognosis of gastric cancer patients[J].Cancer Res Prev Treat,2020,47(5):346-352.
[15]	ZHENG Z, BU Z, LIU X, et al. Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications[J].Chin J Cancer Res,2014,26(1):104-111.
[16]	FRIGOLA X, INMAN B A, KRCO C J, et al. Soluble B7-H1: differences in production between dendritic cells and T cells[J].Immunol Lett,2012,142(1-2):78-82. doi:10.1016/j.imlet.2011.11.001pmid:22138406
[17]	AMATATSU M, ARIGAMI T, UENOSONO Y, et al. Programmed death-ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer[J].Cancer Sci,2018,109(3):814-820.
[18]	BORGHAEI H, PAZ-ARES L, HORN L, et al. Ni-volumabversusdocetaxel in advanced nonsquamous non-small-cell lung cancer[J].N Engl J Med,2015,373(17):1627-1639.
[19]	HERBST R S, BAAS P, KIM D W, et al. Pembrolizumabversusdocetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial[J].Lancet,2016,387(10027):1540-1550.